3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Endometrial Neoplasms
2
Solid Tumors
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Advanced Solid Tumor
1
Interventions
Injections
26
toripalimab
17
pembrolizumab
17
tislelizumab
12
Gemcitabine
8
Cisplatin
7
spartalizumab
6
atezolizumab
6
Irinotecan
6
Carboplatin
6
Paclitaxel
5
Oxaliplatin
5
Nivolumab
5
Leucovorin
5
Fluorouracil
5
camrelizumab
4
Pemetrexed
4
Docetaxel
4
Cetuximab
4
Capecitabine
4
trastuzumab deruxtecan
3
sintilimab
3
olaparib
3
lenvatinib
3
cediranib
3
PM 01183
3
Drug Therapy
3
Cyclophosphamide
3
Bevacizumab
3
Albumin-Bound Paclitaxel
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Advanced Solid Tumor
×
Appointments and Schedules
×
Clear all
NCT06560632
2026-01-16
POLAR
Repare Therapeutics
Phase 1
Terminated
26 enrolled
14 charts